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Current treatment protocols for exposure to nerve and vesicant agents found in the U.S. stockpile ofunitary
chemical weapons are summarized, and the toxicities of available antidotes are evaluated. The status of the
most promising ofthe new nerve agent antidotes is reviewed. In the U.S., atropine and pralidoxime compose
the only approved antidote regimen for organophosphate nerve agent poisoning. Diazepam may also be used
ifnecessary to control convulsions. lb avoid death, administration must occur within minutes ofsubstantial
exposure together with immediate decontamination. Continuous observation and repeated administration of
antidotes are necessary as symptoms warrant. Available antidotes do not necessarily prevent respiratory failure
orincapacitation. Thetoxicity ofthe antidotes themselves andthe individualized natureofmedical carepreclude
recommending that autoinjectors be distributed to the general public. In addition, precautionary administra-
tion of protective drugs to the general population would not be feasible or desirable.
No antidote exists forpoisoningby the vesicant sulfurmustard (H, HlD, HT); effective intervention can only
be accomplished by rapid decontamination followed by palliative treatment ofsymptoms. British anti-Lewisite
(BAL) (2,3-dimercapto-1-propanol) is the antidote ofchoice for treatment ofexposure to Lewisite, another po-
tent vesicant. Experimental water-soluble BAL analogues have been developed that are less toxic than BAL.
Treatment protocols for each antidote are summarized in tabular form for use by health care providers
Introduction
The U.S. stockpile of aging lethal unitary chemical wea-
pons and agents is currently scheduled for destruction by
April 30, 1997, underthe Department ofDefense Authoriza-
tion Acts (PL 99-145 and PL 100456). Unitary weapons
contain lethal agents at the time of assembly, in contrast
to binary weapons containing agent precursors that mix upon
firing and react to form lethal agents. Thus, the deteriorating
unitary weapons stockpile poses a threat in storage as well
as inhandlingduringdisposal. The stockpiled chemical agents
include the organophosphate nerve agents GA (tabun; N,N-
dimethyl phosphoroamidocyanidate, ethyl ester), GB (samn;
methylphosphonofluoridate isopropyl ester), and VX [S-
(diisopropylaminoethyl) methylphosphonothiolate o-ethyl
ester] and the vesicant (blister) agents H/HD [sulfur mus-
tard; bis(2-chloroethyl) sulfide], HT: 60% HD and 40% T
orbis[2(2-chloroethylthio)ethyl] ether, and Lewisite [dichloro
(2-chlorovinyl)arsine]. These agents were specifically de-
signed to cause incapacitation or death in military use and
are quite effective due to their high toxicities at low doses.
The unitary stockpile is housed at eight locations in the
continental U.S. in the form of various weapons (bombs,
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cartridges, mines, projectiles, rockets), spray tanks, and ton
containers (Fig. 1). Two locations, Aberdeen Proving Ground
(near Edgewood, Maryland) and Pueblo DepotActivity (near
Pueblo, Colorado) store only mustard agent, while the rest
stockpile both nerve andblister agents. Agents GB and VX
compose mostofthe nerve agentinventory; a small amount
ofGA is housed only at Tooele Army Depot near Salt Lake
City, Utah.
An analysis of the available antidotes for each nerve and
blister agent in the stockpile was performed as a part of
evaluating the options ofon-site destruction versus transport
to a regional disposal facility (1). Current decontamination
and treatment protocols, antidote toxicities, and the status
ofrecently developed antidotes were evaluated. The study
objectives were to compile what is known about antidotes
and treatment protocols and to make this information avail-
able for evaluation ofthe risks entailed in various stockpile
destruction options and for use by health professionals in
community emergency planning.
The essential nature of emergency planning was high-
lighted in the Final Programmatic Environmental Impact
Statement (1) for the Chemical Stockpile Disposal Program
(CSDP); the probabilities of individual accidents with off-
site consequences during the disposal program range from
lxlO-4 to lxlO-10 for the entire stockpile (1,2). Thus, the
probability ofaccidents occurring is low butconsidered credi-
ble (i.e., requiring emergency preparedness at probMUNRO ET AL.
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FIGURE 1. Unitary chemiical weapons stockpile distribution throughout the U.S. (snmal quantities of GA and Lewisite are also stored at Tooele Army Depot).
abilities 210-8(3). In the event of an accident during the
CSDP, the average maximum number of fatalities is esti-
mated to be over 500, ranging from 1 to more than 1400
under conservative most likely weather conditions (3).
(Average maximumfatalities is the average ofthe maximum
potential fatalities within 20 km for all accidents at all sites
involving all munitions types for both the on-site disposal
and continued storage options, since storage will continue
until stockpile destruction is complete.) Under worst-case
meteorological conditions, the potential maximum number
offatalities for credible accidents during the CSDP is esti-
mated to range from 1 to 5400, where the wind carries
the plume over the area oflargest population density (1).
It should be notedthatthe estimated fatalities fromcredible
accidents for the continued storage option are significantly
higher than those foron-site disposal foral sites but one (1).
These large numbers of estimated fatalities stem from
the fact that several sites have significant populations so
near that to alert and evacuate or protect them once a
release was detected may be difficult (3). For example,
three sites are moderately populated (between26,000 and
41,000 persons within 10km), andthree more have popula-
tions of4,000 to 7,000 within that distance (1). The 10-km
perimeteris considered the immediate response zone, with
less than a 1-hr response time for most accident scenarios
(3).
Hence, inadvertent release could have a catastrophic
effect on the surrounding civilian population. The difficulty
of preventing fatalities is heightened by the necessity for
emergency and medical personnel to work in full protec-
tive gear while treating and decontaminating victims and
decontaminating all equipment used on exposed patients
(4). Such difficulties may be exacerbated by the need to
evacuate medicalfacilities shouldtheybe inthe contminated
area; access to such facilities would be impossible for an
indefinite period thereafter (5).
Furthermore, the widespread possession and the recent
documented use of mustard, cyanide gas, and probably a
nerve agent by Iraq against civilian (6) as well as military
targets in Iran has raised fears that such use may expand
to otherregional conflicts (7). The potential for use by ter-
rorists against civilian populations also exists. Such devel-
opments add weight to the need for aheightened awareness
among civilian medical personnel and emergency planners
ofthe mode ofaction ofchemical warfare agents, the nature
of available antidotes, and treatment protocols.
Neive Agent Exposure
The nerve agents in the unitary weapons stockpile are
organophosphate esters chemically similar to organophos-
phate pesticides but withhigheracute toxicity. For example,
while the rat dermal median lethal dose (LD50, mg/kg) is
only 0.1 for VX and2.5 for GB, it is 6.8 for parathion, 4000
for sevin, and 4400 for malathion (5). Nerve agents are ab-
sorbed by several routes and are hazardous in vapor, liquid,
or aerosol form. They are colorless, generally odorless,
tasteless, and nonirritating to the skin, so exposure to a
lethal dose can occur without being perceived by the indi-
vidual. These agents act by inhibiting the enzyme acetyl-
cholinesterase (AChE), which breaks down the neurotrans-
mitter acetylcholine (ACh) and prevents its excessive
accumulation at nerve endings. The symptoms resulting
from nerve agent exposure are primarily the consequence
of accumulation of excess ACh at nerve junctions where
ordinarily small amounts of ACh are needed for impulse
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transmission. Excess build-up ofACh within portions ofthe
nervous system controlling smooth muscle, cardiac muscle,
and endocrine-exocrine functions can cause some or all of
the following symptoms: drooling, increased bronchial secre-
tions, bronchoconstriction, miosis, excessive sweating,
vomiting, diarrhea, abdominal cramping, involuntary urina-
tion, and cardiac arrythmias (8). Within the central nervous
system, ACh accumulation can result inheadache, anxiety,
confusion, restlessness, giddiness, EEG changes, or even
convulsions and coma, depending on agent and dosage (8).
When skeletal muscles are affected by ACh accumulation,
there can be ageneralized weakness, twitching, and cramp-
ing. Respiratory failure is the immediate cause ofdeathfrom
lethal doses, and is the result of excess ACh not only in
the peripheral nervous system (neuromuscular blocks, in-
creased lung secretions) but also in the central nervous
system (depression of the respiratory center). Dunn and
Sidell (9) describe variations in nerve agent effects with
different routes and degrees of exposure.
The nerve agents also have pharmacologic effects other
than AChE binding (noncholinergic effects), but the acute
toxic effects, especially those involved in respiratory failure,
are generally accepted as beingcholinergic. Adetailed review
of nerve agent toxicity is found in the Chemical Stockpile
Disposal Program Final Programmatic Environmental Im-
pact Statement (1) and is summarized by Watson et al. (5)
and Carnes and Watson (2).
The two main nerve-agent constituents ofthe stockpile
differ markedly in their volatility and consequent potential
health effects. VX, the most potent ofthe stockpile agents,
is the least volatile (10.5 mg/m3 saturated air concentra-
tion at 250C) and would not disperse as widely as GB, a
highlyvolatile agent (22 x104 mg/m3 saturated airconcentra-
tion at 250C) (2). VX, unlike GB, could therefore persist
in the environment and on the skin long after an exposure.
Decontamination
If exposure has resulted in skin or clothing contamina-
tion, the individual must be removed from the affected area
and immediately decontaminated. This should be done by
trained andprotected emergencypersonnel, taking utmost
care to avoid self-contamination. Procedures are detailed
for battlefield situations by Sidell (4,10) and would need
adaptation for civilian applications. Decontamination can be
effectedby removing all contaminated clothing andblotting
(not swabbing or wiping) the skin with an alkaline solution
on wipes from the M258A1 Army Decontamination kit or
with resin-based wipes from the M291 kit (11) followed by
0.5% sodium hypochlorite (HTH) (a 1:9 dilution ofhouse-
hold bleach). If these kits are not on hand, decontamina-
tion can be effected by using 0.5% HTH (12) or most any
alkaline substance (4,10). In the absence of an M291 kit,
washing with copious amounts of water or weak alkaline
solution will remove the nerve agent but will not break it
down. Thus, the contaminated washwater must be con-
tained and disposed of. The adequacy of decontamination
can be assessed by using ABC-M8VGH detection paper
afterthorough washing andthenwashingagain as necessary
(4,10). Unless the exposure is known to be only to nerve
agent, any bleach or alkaline decontaminant must be re-
moved before using the detection paper as it will react to
bleachby turningred, a positive reaction for mustard agent.
Nerve Agent Antidotes in Current Use
The choice ofappropriate treatment fornerve agent poi-
soning depends on the agent and the extent and route(s)
ofexposure. Very mildexposure to nerve agentvapor may
necessitate only decontamination and observation; severe
exposure to vapor orliquidrequires immediate decontanina-
tion, administration ofantidotes, establishment ofartificial
respiration (13,14), continuous monitoringfor at least24 hr
in order to tailor the antidote dose to the individual vic-
tim's clinical condition, and intensive supportive therapy
over hours or days to maintain life.
Immediate care is vital to prevent death from respiratory
failure, which can occur within minutes or even seconds
in cases of massive inhalation exposure (15). Monitoring
of the AChE level provides retrospective confirmation of
poisoning but is not likely to be helpful in managing the
patient during the acute phase. Prompt attention is also
necessary because the agent-AChE complex becomes resis-
tant in various degrees to reactivation by oxime-type anti-
dotes within minutes to a few hours, depending on the
agent. The standard antidotes available clinically in the U.S.
are atropine (ananticholinergic drug) andpralidoxime (Proto-
pam or 2-PAM-Cl). In addition, central nervous system
(CNS)-active drugs such as diazepam (Valium) maybe used
if convulsions occur.
Atropine. Atropine is used to antagonize the excess ACh
that accumulates at nerve endings in the absence of func-
tional AChE. It counters the bronchoconstriction andbron-
chosecretions that interfere with breathing or support by
a respirator. Atropine also opposes the agent's toxic effects
of nausea, vomiting, and diarrhea. It partially relieves the
CNS respiratory depression but cannot reverse respiratory
muscle paralysis (13,16).
Therapy for nerve agents is similar to that for organo-
phosphate pesticides but usually requires higherinitial atro-
pine dosage and more frequent administration in the first
several hours after exposure. However, it does not usually
require as prolonged administration of atropine (Table 1)
(4,15,17; F. R. Sidell, personal communication). Sidell
(4,10,15) recommends 2 to 8 mg atropine intramuscularly
(IM) or intravenously (IV), depending on the severity of
symptoms. Injections should be given every 3 to 8 min or
longer until decreased lung secretions and pulmonary resis-
tance are seen. Ifthe victim experiences only mrid breathing
difficulties ormildgastrointestinal distress, aninitialatropine
dose of2 mg IM may suffice (4,10). In one case ofaccidental
GB inhalation, initial injection of4 mg atropine (2 mg IV+
2 mg IM) was followed by several2-mg (IV except for one
IM) doses over the next 2 hr. Pralidoxime was also re-
quired (18). Limitedexperience with nerve agent casualties
indicates that 10 to 20 mg cumulative doses in the first 2
to 3 hrusually provides adequate control ofsymptoms (9).
Fororganophosphate pesticide poisoninginchildren, Haddad
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Table 1. Nerve agent antidote summary: actions, dosages, side effects/overdose symptoms.
Antidote/action
Atropine (di-hyoscyamine)
Anticholinergic alkaloid: used to blockeffects of
parasympathetic nerve stimulation. Prepared
from powdered roots of Atropa belladonna
andDatura stramonium. In massive doses,
used to treat AChE poisoning and to man-
age certain psychiatric states.
Relieves smoothmuscleconstriction inlungand
GI tract and reduces glandular paralysis
(cleans up respiratory tract secretions).
Toxicity rating 5, extremely toxic.
[Probable oral lethal dose in humans of5-50
mg/kg, or 7 drops to 1 teaspoon for 150-lb
(70-kg) person].
2-PAM-Cl (protopam chloride; 2-pyridine aldox-
ime methyl chloride; pralidoxime)
Treat poisoning due to organophosphate
insecticides and nerve gases; anticholines-
terase antagonist. Effective when given
with atropine. a
Acts by removing organophosphate from
cholinesterase andrestoringnormalcontrolof
skeletal muscle contraction (relieves twitch-
ing and paralysis). b
aFrom Gosselin et al. (17).
bFrom Sidell (4,10).
CFrom Sidell (15).
dF. R. Sidell, personal communication.
Dose
Adult: 2-4 mg or more of atropine sulfate IM
or IV. Full atropinization maintained at 2-mg
doses every 3 to 8 min for several hours.
Child: initial dose, 0.05 mg/kg.
Maintenance doses for child range from 0.02
to 0.05 mg/kg.
Mean lethal dose unknown (recovery after inges-
tion of 1000 mg documented); lethal estimate
of 10 mg, although recovery documented at
100-mg dose in many adults; children more
susceptible.
For all: provide atropine until signs of atropini-
zation occur (dry mouth and drylungs); use un-
til signs of improvement are seen; taper off
dose. c
Adult: 1-2 g in 100 mL saline IV over 15-30
min for initial dose. Second dose after 1 hr if
symptoms indicate.
Children: initial dose of15-25 mg/kg, followed by
second after 1 hr if symptoms indicate.
Infants: try 15 mg/kg.d
Less effective after aging (when bond between
organophosphate and cholinesterase becomes
irreversible). Substantial aging occurs within 5
hr for GB.b
Overdose symptoms, managementa
Symptoms
Dryness of mucous membranes, burning pain
in throat, difficulty inswallowing, and intense
thirst.
Skin hot, dry, flushed. Rash over face, neck,
and uppertrunk, especially in infants and chil-
dren. Peeling of skin may follow.
Exceptionally high fever.
Sinus tachycardia (rapid heart beat), palpita-
tions, elevated blood pressure.
Uncommonly: nausea, vomiting, and abdom-
inal distensionin infants, urinaryurgency and
hesitancy; inability to void.
Restlessness, fatigue, excitement and confu-
sion, progressing to mania and delirium,
which may persist for hours or days. Hallu-
cinations, particularly ofvisual type. Patients
may exhibit self-destructive acts.
Management
Treat symptoms with physostigmine salicy-
late. Onset of symptoms within 15-30 min,
maximum effects at 2-3 hr and recovery
within 12 hr.
Symptoms
Rapid and possibly dangerous rise in blood
pressure.d
Temporary rapid heart beat (tachycardia).
Mild weakness, dizziness.
Blurred or double vision.
Management
Usually well tolerated with careful (slow)
administration.
and Winchester (19) recommend 0.05 mg/kg atropine IV,
followed by maintenance doses of 0.02 to 0.05 mg/kg as
needed. In cases of nerve agent exposure by vapor or on
the skin, atropine canbe administered quickly to adults from
the armedforces MARK I Nerve AgentAntidote Kitifavail-
able. One kitprovides one autoinjector containing 2 mg of
atropine citrate and another containing 600 mg of prali-
doxime chloride (9).
Atropine itself is highly toxic, with a rating of about 5
on a scale of 1 to 6, 6 being most toxic; the probable oral
lethal dose for humans at this rating is given as 5 to 50
mg/kg [7 drops to 1 teaspoon for a 150-lb (70-kg) person]
by Gosselin et al. (17). This antidote must therefore be
used with caution andonly with sure knowledge that nerve
agent exposure has already occurred. This precaution is
ofparticular importance withregard to children, the elderly,
ordebilitated individuals. In the absence ofexposure, a2-mg
dose to an older person might result in "a greater degree
ofmental disturbance, including delirium, and the rapid heart
rate might cause heartdamage orprecipitate anarrhythmia"
(19). The major consequences ofatropine overdosage are
listedinTable 1. However, in cases ofsevere organophos-
phate exposure, by far the main treatment error has been
atropine underdosage, rather than overdosage, because of
the large doses required (17). Rapid administration of
atropine to a cyanotic person may be dangerous, as Krop
and Kunkel (20) occasionally observed fatal ventricular
fibrillation in anoxic dogs and cats that they attributed to
atropine given after GB exposure. However, in nerve agent
poisoning it may not be possible to correct anoxia prior to
giving atropine because ofthe intense bronchoconstriction,
heavy bronchosecretion, and even lockjaw (trismus) that
are characteristic of severe poisoning (17). In such cases,
atropine administration may be necessary to relieve these
symptoms so that respiration may be restored.
Monitoring ofbody temperature may also be indicated,
particularly in infants and children, because atropine can
cause exceptionally high fever (17). This may or may not
be a problem in human cases of nerve agent exposure
because nerve agents induce hypothermia in rodents (21).
Hypothermia has apparently been noted in humans in a few
cases ofsevere organophosphate pesticide exposure (21).
Pralidoxime. In a clear case of nerve agent exposure
and with established symptoms beyond miosis (pinpoint
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Table 2. Older oximes: nomenclature and abbreviations.
Abbreviation
Trivial name or trade name Chemical name Structurea
Pralidoxime chloride 2-PAM-Cl Pyridine-2-aldoxime methyl chloride CH-CNOH Cl-
*-CH,
Pralidoxime methane P2S N-methyl-2-pyridiniumaldoxime CH-NOH CH3SO4
sulfonate methanesulfonate X
CD?-CH,
Obidoxime Toxogonin bis[(4-Hydroxyiminomethyl)-pyridine- HON=MC -<Y)-CH,OCH,-*J \ Cm-NOH 2Cl
1-methyl]-ether dichloride
Trimedoxime TMB4 N,N'-Trimethylene bis(pyridium-4- NONCHCH&I(CN,) I NOH 2Cl
aldoxime) dichloride
(or dibromide)
aAdapted from Stares (13).
pupils) ortearing, a second antidote should be administered
to complement the actions ofatropine. Pralidoxime chloride
is currently the only oxime antidote approved by the U.S.
Food and Drug Administration (FDA) for clinical use in
organophosphate poisoning. Its active oxime group, RCH=
NOH, dissociates the nerve agent moiety from the AChE
molecule, reactivating the enzyme and gradually restoring
normal muscle function. The major effect of oximes is to
restore skeletal muscle function; pralidoxime has little or
no CNS effect, possibly because it does not seem to cross
the blood-brain barrierreadily (16). Commonnames, abbre-
viations, chemical names, and structures of pralidoxime
chloride, pralidoxime methane sulfonate (P2S), and two
other oximes are displayed in Table 2 (13). As listed in
Table 1, the usual adult dosage of pralidoxime consists of
1 to 2 g for a 70-kg person (14-28 mg/kg) IV in 100 to
150 mL of saline given slowly over 15 to 30 min (17,22).
Blood pressure should be monitored carefully during the
infusion. The initial dose may be followed by two or three
periodic maintenance doses over a period ofnot more than
48 hr if muscle weakness persists and if the initial dose
proves beneficial (23) or for as long as it appears to be of
help. A suggested initial dose for children is 15 to 25 mg/kg
according to F. R. Sidell (personal communication). Barr
(22) recommends 25 mg/kg. No data are available on which
to base a dose for infants, but Sidell recommends an initial
dose of 15 mg/kg.
The limits on oxime use result both from the aging of
poisoned AChE and from the toxicity of the oxime (23).
Aging ofagent-bound enzyme is thought to result from the
loss ofanalkyl oralkoxy group fromthe nerve agentmoiety
(16). The remaining enzyme-modified nerve agent complex
is more stable and is resistant to reactivation by oximes
or similar antidotes. The rate and extent ofagingvary with
the nerve agent in question. Inhumans, aging is substantial
(50 to 60%) within 5 to 6 hr after GB exposure but less
extensive (approximately 40%) even 48 hr afterVX expo-
sure (24).
Because ofthe AChE aging problem, prompt administra-
tion of an oxime antidote is essential and can be facilitated
ifnerve agent antidote kits are avaflable to emergency medi-
calpersonnel and to the workers involved in decommission-
ing nerve agent stockpiles. They can be used for self-
Table 3. Acute toxicity of 2-PAM-Cl and two H-oximes
in four species.'
Route of LD5, mg/kg ± SE
Species injection 2-PAM-Cl HI-6 HGG-12
Mouse IP 162 ± 4 670 ± 44 177 ± 9
Rat IM 206 ± 3 860 ± 28 1179 ± 36
Guinea pig IM 184 + 2 500 ± 14 281 ± 4
Dog IM 75 ± 2 350 ± 10 60 ± 4
aAdapted from Boskovic et al. (26).
administration or administration by another.
Because pralidoxime itselfis toxic, it must be used with
caution. The patient must be monitored closely for hyper-
tension when the drug is given IV because rapid infusion
will produce a marked andpotentially dangerous rise inblood
pressure, as well as double vision, nausea, and vomiting
(15). Mild weakness, dizziness, blurred vision, doublevision
(diplopia), and temporary rapid heartbeat have often been
seen in normal subjects given doses as low as 0.5 g. At
higher than therapeutic doses, pralidoxime caninhibit AChE
and block neuromuscular transmission (16,23,25).
According to Sidell (15), there has been little use ofthis
drug in children or elderly persons. Because these groups
are generally more sensitive to drugs, it may be expected
that these side effects might be more severe or be seen
at lower doses in these populations.
LD50 values for pralidoxime and two other oximes in four
species are compared and presented in Table 3 (26). This
oxime is substantially more toxic to dogs than to any ofthe
three rodent species tested. It is of interest to note that
the LD50 for dogs (75 mg/kg) is not much greater than the
therapeutic dose range (15-30 mg/kg) in humans. Calesnick
et al. (27) studied the toxicity of pralidoxime, its methane
sulfonate salt (P2S), and trimedoxime (TMB4) in human sub-
jects. Of the three, pralidoxime was least toxic, P2S
somewhat more toxic, and TMB4 most toxic, especially
whengiven orally overextendedperiods oftime ratherthan
in a single dose.
Therapy for CNS Effects
In addition to the use ofatropine andpralidoxime, therapy
for other CNS effects may be needed. McLeod (28) cites
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evidence forextensive brainlesions produced inexperimen-
tal animals by GB and attributes it to seizure activity that
kills neurons. Anticonvulsants such as diazepam have been
used effectively in some experimental animals (29-31). On
the basis of increased animal survival, diazepam is a part
ofthe nerve agent treatment regimen adopted by the U.S.
and the U.K. for military service use (9,32). Other CNS
effects have been noted in clinical situations after the acute
phase of poisoning has passed. Scopolamine, a compound
related to atropine, has been useful in relieving nonlethal
but disagreeable and potentially disabling psychological side
effects ofnerve agent exposure. A patient who had expe-
rienced a severe exposure to GD (soman; pinacoyl methyl
phosphofluoridate) (a nerve agent chemically related to GA
and GB, but not part ofthe stockpile ofunitary weapons)
suffered from temporary depression, bad dreams, de-
creased alertness, and disturbed sleep patterns during the
recovery period after atropine and pralidoxime treatment
(18). Administration ofscopolamine hydrobromide produced
amarkedimprovement in mentalfunction (18). Very severe
acute organophosphate pesticide exposure or chronic expo-
sures have resulted in abnormal EEG patterns and avariety
of neuropsychiatric symptoms varying in severity from
anxiety to hallucinations (17). Thus, the treatment ofnerve
agent poisoning may require substances whose CNS activ-
ity can counteract deleterious effects not adequately
opposed by atropine and pralidoxime. Clearly, these treat-
ment agents are not needed until the acute effects ofexpo-
sure have subsided and any psychological side effects have
appeared.
Newer Oximes
A search has continued for an oxime orrelated compound
that would combine high effectiveness (33,34) against all
the nerve agents with low toxicity (35) and good chemical
stability. To date, no ideal compound has been identified,
although several promising substances have emerged.
A so-called H-series of oximes has been synthesized in
the laboratory ofInge Hagedorn ofthe University ofFrei-
burg in West Germany. Of these, HI-6 and HS-6 appear
to be among the most effective and least toxic. In addi-
tion, HGG-42 and HGG-12 have shownpromise. The struc-
tures of these oximes are illustrated in Table 4 (34).
Toxicityvalues forHI-6 andHGG-12 inmice, rats, guinea
pigs, and dogs are compared in Table 3 with those for
pralidoxime (26). Interestingjy, the H-oximes are also more
toxic in dogs than rodents, as noted earlier forpralidoxime.
HI-6 appears to be well toleratedbyhealthy human volun-
teers (36). Overall, HI-6 is apromising candidate toreplace
pralidoxime, but is not expected to be available during the
lifetime ofthe CSDP since clinical testing and FDA approval
would be necessary for its use.
Pretreatment Regimens
In addition to the development ofnew oximes, combina-
tions ofothertherapeutic agents with atropine and oximes
have been examined. A promising approach has been to
Table 4. Newer oximes: nomenclature and structure.a
Abbreviation Structure
HI-6 r1C ,O2CH,-I CONM, 2Cl
-
CH=NOH
HS-6 QN-CH,OCH,-V 2Cl
-
CH=NOH CONH,
HGG-12 Q -CH,OCH, < e 2H20
CH=NOH
0
HGG-42 Q2CHOCH20NQ
CH-NOH C
0
aAdapted from Lenz and Maxweli (34).
pretreat with carbamate compounds that are, themselves,
anticholinesterases. The carbamate protects a fraction of
AChE from blockage by nerve agent; the carbamate moiety
then spontaneously hydrolyzes from the AChE molecule
within a matter of hours.
Pretreatment is a part ofthe approach adopted recently
by the United States and the United Kingdom for those
military personnel considered at risk ofnerve agent attack.
The U.K. plans to use a combination ofP2S, atropine, and
diazepam together with pyridostigmine (a carbamate) pre-
treatment (32,37). The U.S. will distribute pyridostigmine
bromide tablets (30 mgevery 8 hr) to combatunits equipped
with atropine and pralidoxime autoinjectors; diazepam will
also be available via aid men (9). Pretreatment withpyrido-
stigmine substantially increases the protective effects of
atropine and P2S against the lethal effects of GB and VX
inguinea pigs, and the addition ofdiazepam as a therapeutic
agent further enhances survival (32). The improvement in
protection afforded guinea pigs by adding pyridostigmine
pretreatment and diazepam as supportive therapy in addi-
tion to atropine and oximes is compared in Table 5 with
the values foratropine and oxime alone (31). The basis for
comparisonis the protective ratio, thatis, the ratio ofLD50
withtreatment to LD50 without treatment. The higher the
value, the more protection is afforded by the therapeutic
combination.
A related carbamate, physostigmine, has been shown to
protect animals against not only nerve agent lethality, but
also incapacitation. Physostigmine (a compound that enters
the CNS more readily than pyridostigmine), when used
together with aprophen (an anticholinergic) as a pretreat-
ment, gave betterprotection in guinea pigs than did pyrido-
stigmine alone orin combination with aprophen against both
death and incapacitation by GB (37). In both cases, post-
poisoning therapy consisted ofatropine, P2S, and diazepam.
Physostigmine, like pyridostigmine, is widely used clinically
forthe treatment ofmyasthenia gravis (16). However, ithas
not been approved for use in humans as a pretreatment
against nerve agent exposure since it causes undesirable
side effects at the necessary doses (9).
Other current and promising research directions aimed
at countering nerve agent exposure in humans include pre-
exposure loading of animals with an excess of circulating
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Table 5. Therapeutic value of oxime antidotes against GA, GB,
and VX with pyridostigmine pretreatment in guinea pigs. a
Protective ratiob
Antidote
No oxime
P2S
HS-6
HI-6
HGG-12
HGG-42
TMB4
Toxogonin
Dose,
mg/kg
0
30
47
49
81
82
46
47
GA
Withoutc Withc
1.3 11
2.5 34
2.6 73
2.2 34
3.7 68
- 12
13 76
19
GB
Without With
<3 11
38 45
35 57
76 110
12 54
- 40
46 220
59 380
vx
Without With
<3 15
25 69
9.6 82
66 68
5.1 55
- 31
40 310
58 410
aAdapted from Inns and Leadbeater (31).
bProtective ratio = LD50 with treatment / LD50 without treatment.
cWithout, without pyridostigmine and diazepam; with, with these com-
pounds; pyridostigmine (0.084 mg/kg IM) given 30 min before nerve agent
(SC). One minute after nerve agent, antidote given IMtogether with 14mg/kg
atropine; diazepam (1.8 mg/kg) given IM immediately after atropine plus anti-
dote mixture.
ChE to bind nerve agent before it can reach tissue AChE
sites (38) and the use of monoclonal antibodies (9,39) or
carboxylesterase (40) and other nerve agent-inactivating
enzymes (41) as protective systems. Again, while these
approaches have likely value in military applications, they
are in the research stage and are not at all likely to be avail-
able for consideration of use during the CSDP.
Protection of Civilian Populations
Given the potentially catastrophic effects of an inadvertent
release of nerve agent with off-site exposure of the sur-
rounding population, the distribution of antidotes of auto-
injectors and/or prophylactic doses ofpyridostigmine were
considered inthe Final Programnatic EnvironmentalImpact
Statement (1). The severe and possiblylife-threatening toxic
effects of even a 2-mg dose ofatropine and ofpralidoxime
(15) were acknowledged to be a realistic consequence of
inappropriate self-administration. Children, elderly, and
those with cardiovascular conditions are considered par-
ticularly sensitive groups. The resulting recommendation
is that antoinjectors not be distributed to the public. A fur-
ther consideration in making this decision is the possibility
ofsubstance abuse with atropine, a hallucinogen (Table 1).
Extended pretreatment of the general population with
pyridostigmine also poses the problem oftoxic side effects
in the event of an inadvertent overdose (9) which might
be exacerbated in very young, elderly, or otherwise sensi-
tive members ofthe civilian population. These side effects
may include decreased visual acuity/accommodation and
gastrointestinal effects. The visual effects could easily lead
to severe consequences for an unsuspecting individual
attempting to drive or perform other vision-dependent
hazardous tasks. Thus, in a civilian population, extended
pretreatment (prophylaxis) is not feasible or desirable.
Vesicant Agent Therapy
The blister agents, mustard and Lewisite, are very toxic
but are not acutely lethal at the extremely low doses char-
acteristic of nerve agent toxicity. Rather, they were
designed as effective incapacitating agents. Mustard agent
in its various formulations is an alkylating agent that com-
bines irreversibly with the proteins and nucleic acids ofthe
cells it contacts. The signs of mustard poisoning are
reviewed in detail elsewhere (1) and summarized in Watson,
Jones, and Griffin (42). Mustard exposure is insidious in
that there is usually a latent period ofseveral hours before
the toxic reactions appear. The most sensitive end point
is eye irritation; skin rashes orblisters occur at larger doses
and all exposed mucus membranes are susceptible to irri-
tation, e.g., the respiratory tract membranes in an inhalation
exposure. Latent effects such as vision impairment, chronic
bronchitis, and skinandlungcancers are known tobe caused
by the large mustard exposures possible in warfare or in
weapons factories during World Wars I and II (42).
The acute andlatenttoxiceffects ofLewisite are reviewed
in detail elsewhere (1). Lewisite produces immediate severe
pain upon skin and eye exposure; it kills cells on contact
by poisoning essential cell enzyme systems rather than by
alkylating reactions. It is also a systemic poison, damaging
the liver, gallbladder, and bile ducts and evenkidneys and
urinary tract athigher doses. Itis implicated as a carcinogen
at sublethal doses that cause blistering and pain.
Sulfur Mustard
There is no specific antidote known for sulfur mustard
poisoning (43-45). Mustard is highly reactive chemically
and forms a chemical bond with many biological molecules.
Once this bond is formed, the reaction is irreversible for
all practicalpurposes. Attempts to remove the mustard res-
idue from biological molecules have been unsuccessful,
except with drastic chemical procedures that would be
injurious tolivingtissue (45,46). Treatmentofsulfurmustard
poisoning in humans has focused on rapid decontamination
followed by symptomatic therapy (47). Discussions in U.S.
Army manuals of therapy for various chemical warfare
agents correctly emphasize that instantaneous removal of
mustard from body surfaces is the best form oftreatment
(48). The recommended way to accomplish this is by
washing with dilute household bleach (0.5% HTH) or
copious amounts ofsoap and water (49,50). A study ofthe
potential use ofhousehold products to remove mustard from
guineapig skin (51) indicated that most suchproducts (tissue
paper, flour, talcum powder, washing abrasive, salad oil,
etc.) were effective inreducingskin damage ifappliedwithin
4 min ofcontamination. Flour sprinkled onthe contaminated
skin, followed by removal ofthe flour with wet tissue paper
is particularly effective for physical removal, but does not
chemically neutralize sulfur mustard. Neutralization is most
readily accomplished by use of a 0.5% HTH solution.
U.S. Army documents (11,48,50) that discuss these
chemical warfare agents also provide information regarding
decontamination andfirst aidin the case ofbattlefield expo-
sures. Emphasis is placed uponimmediate decontamination
following exposure to the sulfur mustard agents H and HD.
Copious flushing with water for eye contamination and
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bathing with dilute bleach solutions to remove skin contam-
ination is recommended. Fuller's earth powder (which is
usedto adsorb liquid agent droplets) and chloramine powder
(which reacts chemically with mustard) are effective skin
decontaminants and have been supplied to military personnel
in field kits in the past (45,52). The chloramine reaction
alters mustard's chemical structure so that it no longer
reacts with biological molecules. The chloramines, along
with effective equipment decontaminants such as hypo-
chlorite, operate by producing free chlorine, which chemi-
cally reacts with mustard (45,52). Such chemicals could be
useful inreducing skin damage inaccidentally exposed popu-
lations (ifapplied quickly enough after exposure). However,
these chemicals can neither be used in the eye nor to alle-
viate respiratory tract damage. The current M258A1 skin
decontamination kit will shortly be supplanted by a resin-
based M291 skin kit that is easier to use (11).
Treatment and decontamination procedures described
above for mustard agent are effective for HT exposure as
well. Because HT is considered to be more toxic than HD,
swift removal ofthe agent and treatment ofsymptoms are
imperative. Personnel decontamination canbe accomplished
by washing with copious quantities of either water (HT is
poorly soluble in aqueous solutions) or soap and water.
Chlorine bleach solutions will neutralize HT, as will the
reagents contained in the Army M258A1 and M291 skin
decontamination kits.
Some animal studies have focused on use of drugs that
might react with mustard as a mustard scavenger (47). Rat
studies have indicated that in animals dosed with three times
the LD50 dose of mustard and injected with various drugs
30 min later, the best protective effects (decreased lethality,
fewer pathological organ changes, less loss ofbody weight)
were obtained with a combination of sodium thiosulfate,
vitamin E, and dexamethasone (47). The dosages ofdrugs
used were 3000 mg/kg of sodium thiosulfate, 8 mg/kg of
dexamethasone, and 20 mg/kg of vitamin E. The sodium
thiosulfate was thought to act as a mustard scavenger (i.e.,
simply reacted with mustard); vitamin E is considered an
antioxidant and free-radical scavenger. Dexamethasone is
acorticosteroid, ananti-inflammatory agent. Amongrabbits
receiving a dermal dose of mustard, use of steroid (corti-
sone) injections 15 min after treatment, orcortisone injec-
tions plus hydrocortisone ointment at the site of mustard
application, reduced skin swelling and decreased the thick-
ness of the skin lesion produced by mustard (53). This
therapy did nothastenthe rate ofhealing, however. These
results with laboratory animals suggest that symptomatic
therapy could have beneficial effects in human cases of
mustard poisoning and that mustard scavengers may also
be useful, butthat suchtreatment mustbe initiatedrelatively
quickly after exposure. It is to be emphasized that the
previously described treatments are, to our knowledge,
untested for their efficacy in humans.
Internal exposures do notlend themselves to decontam-
ination and have no specific treatment. Depending on the
dose, inhalation ofmustard vapors will generate inflamma-
tion or ulceration of the respiratory tract and lungs. In
exceptionally severe cases (50-70 mg/m3), death can result
from extensive tissue damage and fluid concentration in the
lungs and trachea. Ingestion ofcontaminated food orwater
would produce nausea, gastrointestinal disturbances and
diarrhea. Symptomatic and supportive therapy are
recommended.
Lewisite
Historically, the antidote of choice for treating Lewisite
and arsenical poisoning in general is the synthetic dithiol,
2,3-dimercapto-1-propanol, developed by British toxicolo-
gists in the years immediately prior to World War II (54).
Known as British anti-Lewisite (BAL), this compound pre-
vents skin vesication from Lewisite exposure after an
untreated time lapse of as much as 1 hr. Intramuscular
administration of BAL will also provide protection from
topical and systemic Lewisite effects by binding arsenic to
the BAL molecule, thus permitting transport ofthe arsenic
complex to the excretory system and removal through the
urine. Nevertheless, therapeutic administration must be
closely monitored because BAL possesses considerable
toxic properties of its own and will interfere with cellular
respiration (54). BALis suitable for muscularinjectiononly.
Recommended treatment and precautions are summarized
in Table 6 (4,17). Following World War II, BAL use was
expanded to include civilian medicine, where it has been
an effective treatment in cases of lead, mercury, copper,
and arsenic poisoning (55).
In the late 1950s, scientists in the Soviet Union and the
People's Republic of China reported success with new,
water-soluble BAL analogues in treating victims ofoccupa-
tional heavy-metal poisoning and in preventive therapy
amongworkers in heavy metals industries (56-59). These
new BAL analogues are the sodium salts of2,3-dimercapto-
1-propanesulfonic acid (DMPS) and meso-dimercaptosucci-
nic acid (DMSA). In addition to being water soluble and
exhibiting less toxicity than BAL, they possess the advan-
tage of oral administration (not a recommended route for
BAL treatment). Recent work in the U.S. demonstrates
that both DMPS and DMSA protect rabbits receiving oral
or subcutaneous (SC) doses ofLewisite from lethal systemic
effects (59). Even when treatment was delayed for 90 min
after Lewisite exposure, all exposed animals survived; in
contrast, between 83 and 100% of the Lewisite-exposed
animals receiving no treatment died (59).
Prelminary experiments on the skin ofswine indicate that
pretreatment with DMPS or DMSA in a thin collagen film
may also be protective againsttheblisteringactionofLewisite
on the skin (59). This technique would have utility for
emergency workers and rescue teams who may need to
entercontaminated areas orhandle/treat contaminated indi-
viduals. Further studies on swine skin have demonstrated
the effectiveness of another compound developed in the
Soviet Union [Mercaptid; 3-p-tolythio)-1,2- propanethiol]
in dealingwith postexposure treatment ofLewisite-contam-
inated skin; topical application ofMercaptid "diminished the
severity ofthe burns" as observed inanonquantitative visual
assay of exposed swine skin (59). Note that swine skin is
considered by many investigators to be reasonably similar
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Table 6. Treatment protocol for British anti-Lewisite (BAL) (2,3-dimercapto-1-propanol) (dimercaprol).
Antidote/action Dose Overdose symptoms, management
Lifesaving inacute poisoning ofarsenicals (except IM intobuttocks indosage of0.5 Symptoms
arsine) and solutions oforganic Hgcompounds. mL/25 lb body weight (com- Consistent objective response is rise in systolic and diastolic
Also for chronic As or Au poisoning. mercial preparation of 10% blood pressure plus tachycardia (rapid heartbeat).
Action by displacing the metal from its combina- BAL inpeanut oil) up to maxi- Nausea and sometimes vomiting
tion with sulffhydryl groups of enzyme mum of4.0 mL. Repeat in 4, Headache
proteins.b 8, 12 hr. For severe cases, Burning sensation of lips, mouth
Toxicity rating 4.very toxic interval shortened to 2 hr.' Feeling of constriction in throat, chest, hands Toxicity rating 4, very toxicCojntvis terig salvaio
(Probable oral lethal dose = 50-500 mg/kgor Conjuncgings, tearing, salivahon
1 teaspoon to 1 ounce for 150-lb [70-kg] Handingling
person.)b Burning sensation in penis Sweating forehead and hands
Abdominal pain
Tremors
Lower back pain
Anxiety, weakness, and restlessness
Tachycardia (rapid heartbeat) and elevated arterial blood
pressure
Persistent fever in children
Occasional painful sterile abcesses at injection sites
Coma and convulsions at high dose (in children, this occurs
at 10, 25, and 40.5 mg/kg) (recovery prompt)b
Management
Symptoms usually subside in 30-90 min; IM use of1:100 solu-
tionepinephrine HCl (0.1 to 0.5 mL) or oralephedrine sulfate
(25-50 mg)b
aFrom Sidell (4).
bFrom Gosselin et al. (17).
to human skin in its reaction to certain surface-active
chemicals.
Dosage and treatment protocols for use of DMPS and
DMSA in Lewisite poisoning have not yet been developed
because these compounds are considered "orphan drugs."
However, DMPS and DMSA have been used to treat sev-
eral isolated cases of arsenic and methylmercury poison-
ing (60,61) and to reduce the body burden of lead among
smelter workers (62). Treatment forone arsenic-poisoned
individual was 300 mg DMSA orally every 6 hr for three
days; the victim recovered. However, prolonged oral treat-
ment (>5 days) with some formulations ofDMPS has been
associated with development ofStevens-Johnson syndrome
(. J. Chisholm, personal communication).
An additional Lewisite antidote that has not seen much
use since the endofWorldWarIIis2,3-dimercaptopropanol
glucoside (BAL-INTRAV), another BAL formulation devel-
oped for IV and SC treatment oftopical Lewisite exposure
andsystemiceffects (63). BAL-INTRAV also demonstrates
a lower mammalian toxicity than BAL (LD50 in rabbits for
BAL-INTRAV is 5000 mg/kg as compared to 50 mg/kg for
BAL) (63). A further advantage ofBAL-INTRAV therapy
is the relatively lengthy time delay that can occurbetween
exposure and treatment with no observed change in suc-
cessful outcome, atleastforlaboratory rabbits. With adelay
of 4 hr, treated rabbits exhibited lesions at the site of
Lewisite application, "but made an uneventful recovery"
(65). Adelayof6.5 hrpermitted eventualfullrecovery after
1 to 3 days of poor appetite and illness. A delay of 12 hr
was fatal to allexposedrabbits (65). The above values were
observed in test populations ofadult rabbits; younger ani-
mals (with thinner skins) were more sensitive to Lewisite
exposure. At the same dose as the adults (1.5 mg/kg), none
of the young rabbits survived a 6.5-hr delay in treatment
with BAL-INTRAV; all survived a 4.0-hr delay.
Although wartime conditions preventedlargerpopulations
of experimental animals from being tested, the investiga-
tions performed by Danielli and his colleagues (63) demon-
strate that BAL-INTRAV has merit in Lewisite therapy,
that time before treatment should be kept at a minimum,
and that young individuals should be treated sooner after
Lewisite contamination than adults.
In the absence of BAL analogues for treating exposed
skin, decontamination may be accomplishedby washing with
water, soap and water, or solutions ofchlorine bleach (0.5%
HTH) or soda (sodium hydroxide), and use of absorbent
powders such as Fuller's earth (49,50,52). As previously
discussed, exposed eyes should be immediately flushed with
large amounts of water or weak solutions of soda or
detergent.
Conclusions
Antidotes or combinations of antidotes are available to
counteract the effects of exposure to GA, GB, and VX.
In adequate dosage, the antidotes must be used in con-
junction with prompt decontamination, intensive monitor-
ing, andindividualized supportive therapy, especiallyin cases
of severe exposure. Incapacitation and respiratory failure
can occur even with prompt antidote administration. The
latter effects can recur after apparentimprovement, so con-
tinuous monitoring and repeated administration ofantidotes
and artificial respiration may be required, especially in the
first 24 hr after exposure. Neither distribution ofatropine
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and oxime autoinjectors to the general public nor precau-
tionary administration of protective drugs to the general
population are recommended.
Since there are no known antidotes for sulfur mustard
poisoning, prompt decontamination becomes of highest
importance. One approved antidote, BAL, exists for Lewis-
ite. Other promising analogues exist that have superior pro-
perties, but they are not generally available.
Management ofdecontamination and immediate treatment
for multiple casualties, particularly in cases ofmoderate to
severe exposure to nerve agents is complex, and the details
of management ofnerve agent as opposed to organophos-
phate pesticide poisoning differ. These facts lead to the
recommendation that medical and emergency aid personnel
(first responders) in the vicinities of chemical weapons
stockpile sites receive training in management of medical
emergencies involving nerve andblister agents prior to the
onset of the CSDP. While on-site trining tailored for first
responders is offered by the Atlanta-based Centers for Dis-
ease Control (2), training geared for physicians is available
from the Chemical Casualty Care Office of the U.S. Army
Medical Research Institute of Chemical Defense at Aber-
deen Proving Ground, Maryland. We recommend that host
communities avail themselves of these resources.
The potential for simultaneous exposure ofa substantial
number ofhumans and the consequent need for significant
amounts of antidotes may require local stockpiling ofanti-
dotes. Pralidoxime may be problematic since itis available
from only one supplier (Wyeth-Ayerst Laboratories, New
York, NY). Inventories ofexistinglocal supplies ofantidotes
anddecontamination kits shouldbe made and adepotsystem
set up in advance of the active phase of the CSDP if pro-
jected needs warrant it.
In summary, a low but credible probability exists for a
catastrophic accidental release (>1000 fatalities) of war-
fare agents during storage or in the course of the CSDP.
Neither antidote autoinjector distribution to the generalpop-
ulation norextended prophylactic pretreatment ofthe popu-
lation withpyridostigmine are acceptable options. Existing
medical resources would be severely strained to deal with
hundreds or thousands ofcasualties requiring decontamina-
tion and treatment. Consequently, every effort must be
made to have trained personnel, decontaminants, and anti-
dotes at hand in advance to provide immediate care and
necessary long-term treatment.
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